Veloxis Pharmaceuticals A/S Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients

Published: Apr 28, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily Envarsus® in stable liver transplant patients in Liver Transplantation.

Help employers find you! Check out all the jobs and post your resume.

Back to news